Although most autoimmune diseases are considered to be CD4 T cell-or antibody-mediated,
many respond to CD20-depleting antibodies that have limited influence on CD4 and plasma …

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …

Objective This study was undertaken to assess the impact of immunosuppressive and
immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in …

Ocrelizumab (Ocrevus®) is an intravenously administered, humanized anti-CD20
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …

Secondary hypogammaglobulinemia (SHG) is characterized by reduced immunoglobulin
levels due to acquired causes of decreased antibody production or increased antibody loss …

COVID-19 vaccination is recommended for multiple sclerosis patients. Disease-modifying
therapies can influence the safety and efficacy of COVID-19 vaccines. RNA, DNA, protein …

Objective To evaluate the clinical consequences of extended interval dosing (EID) of
ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease …

Background COVID-19 vaccination is recommended for patients with multiple sclerosis
(pwMS), while disease-modifying therapies (DMTs) may influence the efficacy of SARS-CoV …

Background: Ofatumumab is approved for the treatment of relapsing multiple sclerosis
(RMS). Ongoing safety reporting is crucial to understand its long-term benefit–risk profile …

Objective The study was undertaken to assess the impact of B cell depletion on humoral and
cellular immune responses to severe acute respiratory syndrome‐coronavirus 2 (SARS …